Tirzepatide, having received FDA approval, has a more defined safety record, though patients should be monitored for potential risks such as pancreatitis or thyroid tumors, which have been concerns with GLP-1 receptor agonists in general
All compounded formulations are prepared by Olympia Pharmaceuticals under cGMP practices and oversight by national and state pharmacy boards.
For oral NMN/NR, bloodwork isn't required the safety profile allows most people to start without testing
Key Benefits of GHK-Cu Skin Rejuvenation: GHK-Cu can firm and tighten loose skin by stimulating collagen and elastin production, restoring the structural proteins responsible for skins bounce and resilience
gastric ulcers, duodenal ulcers, and mucosal erosion where direct local peptide delivery to the damaged tissue is the therapeutic goal Inflammatory bowel conditions: Crohn's disease and ulcerative colitis support, where VEGF-mediated mucosal angiogenesis and anti-inflammatory effects have been investigated Leaky gut and intestinal hyperpermeability: tight junction restoration and mucosal integrity support in patients with compromised gut barrier function Gastroparesis: pro-motility effects via vagal cholinergic pathways investigated in preclinical models of delayed gastric emptying
Visual clarity is not a contamination indicator
